Scaling Clinical Diagnostic Testing to the Masses (Part 1)

The rising cost of health care has hit Americans differently depending on their economic status. There is no shortage of news stories covering the reality of  those with higher incomes having higher life expectancies than those in lower financial brackets. Healthcare services such as clinical diagnostic testing may be out of reach for those who could really use it. So what are some the things a company can do to make clinical diagnostic testing more accessible for everyone? How can an important medical test be affordable to all?

On this episode of Health & Life Sciences at the Edge, host Michelle Dawn Mooney talks with Intel Head of Business Innovation and Life Science Specialist Blake Harlan and SiPhox Chief Product Officer Mike Dubrovsky about clinical diagnostic testing, the way it is used, and the way its use can be improved.

“Clinical diagnostic testing is actually a major part of the [healthcare] system,” says Dubrovsky. “Seventy percent of all medical decisions require diagnostic tests. However, the way that it’s done now is very reactive, so the whole system is based on first the patient having symptoms and then they’re put through a series of tests to try to resolve the problem.” Harlan and Dubrovsky further mention how it’s easy for those in higher income brackets to get tested more often, as those types of tests cost much more than the ones for reactive patients who are presently experiencing symptoms.

“The way the healthcare system works now is it’s really set up to, for the person, once they get sick, to deal with that” says Dubrovsky. He points out how the system is primarily designed to treat reactive care. “The problem is that there is a massive rise in healthcare costs, accompanied with actually a decrease in life expectancy, at least in America”, where six out of ten Americans have at least one chronic disease. In a country that spends so much on healthcare research, Harlan and Dubrovsky think the country needs to shift its thinking and policies when it comes to the health of its citizens.

Learn more about network operations center solutions by connecting with Blake Harlan and Mike Dubrovsky on LinkedIn or visiting SiPhox or Intel Health and Life Sciences.

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Network and Edge Solutions Group.

Follow us on social media for the latest updates in B2B!

Image

Latest

What the Future Looks Like if We Get It Right
What the Future Looks Like if We Get It Right
December 30, 2025

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

Read More
data center infrastructure
AI Is Forcing a Rethink of Data Center Infrastructure at Every Level
December 29, 2025

The data center industry is being redefined by AI’s demand for faster, denser, and more scalable infrastructure. According to McKinsey, average rack power densities have more than doubled in just two years. It went from approximately 8 kW to 17 kW, and is expected to hit 30 kW by 2027. Global data center power demand is projected…

Read More
Emergency department
How Predictive AI Is Helping Hospitals Anticipate Admissions and Optimize Emergency Department Throughput
December 24, 2025

Emergency departments across the U.S. are under unprecedented strain, with overcrowding, staffing shortages, and inpatient bed constraints converging into a throughput crisis. The American Hospital Association reports that hospital capacity and workforce growth have lagged, intensifying delays from arrival to disposition. At the same time, advances in artificial intelligence are moving from experimental to operational—raising…

Read More
Mission
Why Is the Mission of Benchmark So Important
December 23, 2025

As pharmaceutical innovation accelerates, the margin for error narrows, making quality assurance not just a regulatory necessity but a public good. Benchmark’s mission sits at the intersection of progress and protection—helping manufacturers stay aligned with FDA standards so life-saving therapies reach patients faster and safer. By keeping cleanrooms compliant and companies out of trouble, Benchmark…

Read More